Navigation Links
3SBio Inc. Announces Unaudited Second Quarter Results
Date:8/17/2010

1.1% to RMB4.5 million (US$0.7 million).

Gross profit. As a result of continued sales growth from key products, gross profit for the second quarter of 2010 increased by 26.4% to RMB94.8 million (US$14.0 million) from RMB75.0 million (US$11.0 million) for the same period in 2009. Gross margin decreased by 2.2% to 89.8% for the second quarter of 2010 from 92.0% for the same period in 2009. The decrease in gross margin is mainly due to higher depreciation charges attributable to the new production facilities in Shenyang.

Operating expenses. Operating expenses were RMB66.8 million (US$9.9 million) for the second quarter of 2010, or 63.4% of net revenues, compared to operating expenses of RMB49.2 million (US$7.2 million), or 60.3% of net revenue for the same period in 2009. The increase in operating expenses as a percentage of net revenues was largely driven by higher SG&A expenses.

-- Research and development ("R&D") costs. R&D costs for the second quarter of 2010 were RMB5.7 million (US$0.8 million), or 5.4% of net revenues, compared to RMB4.3 million (US$0.6 million), or 5.2% of net revenues for the same period in 2009. -- Sales, marketing and distribution expense. Sales, marketing and distribution expenses for the second quarter of 2010 were RMB47.6 million (US$7.0 million), or 45.1% of net revenues, compared to RMB36.2 million (US$5.3 million), or 44.5% of net revenue, for the same period in 2009. The increase was primarily attributable to higher sales activities in general and continued investment in building the TPIAO and EPIAO brands. -- General and administrative expenses. General and administrative expenses for the second quarter of 2010 were RMB13.5 million (US$2.0 million), or 12.8% of net revenues representing an increase of 56.0% from general and administrative expenses of RMB8.7 million (US$1.3 million), or 10.6% of net revenues for the same period in 2009. '/>"/>

SOURCE 3SBio Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. 3SBio Inc. Announces Second Quarter 2008 Results
2. 3SBio Inc. to Hold Annual General Meeting
3. 3SBio Inc. to Present at the Morgan Stanley Global Healthcare Unplugged Conference
4. 3SBio Inc. Announces Results of Annual General Meeting
5. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
6. 3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO
7. 3SBio Inc. Schedules 2008 Third Quarter Earnings Release on Monday, November 10, 2008
8. 3SBio Inc. Announces Preliminary Third Quarter 2008 Results
9. 3SBio Inc. Files for SFDA Approval of NuLeusin
10. 3SBio Inc. Announces Third Quarter 2008 Results
11. 3SBio Inc. to Present at the Piper Jaffray 20th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , Aug. 31, 2015  US-Australian drug ... NVGN ) today confirmed its comprehensive scientific review ... technology platforms in areas of unmet patient need. ... the remaining preclinical projects prior to entering into ... compounds. Acting Chief Executive Officer, ...
(Date:8/31/2015)... -- Trimb Healthcare AB ("Trimb") today announced that it ... ("YouMedical"), a Dutch OTC company with operations in key ... EUR 16 million, with solid growth and leading brands ... to build a leading international OTC company, and this ... gives us a stronger North European OTC platform, from ...
(Date:8/31/2015)... ... 2015 , ... Proove Biosciences, Inc. is a finalist for the Outstanding Tech ... , Now in its 22nd year, this premier awards event celebrates the best in ... and around the world. The OC Tech Alliance will announce all winners at a ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... studies at the International Spine Intervention Society’ s 23rd Annual Scientific ... August 1st, 2015. With a focus on evidence-based research and clinical application, the ...
Breaking Biology Technology:Novogen Announces The Outcome Of A Comprehensive Science Review 2Novogen Announces The Outcome Of A Comprehensive Science Review 3Novogen Announces The Outcome Of A Comprehensive Science Review 4Novogen Announces The Outcome Of A Comprehensive Science Review 5Novogen Announces The Outcome Of A Comprehensive Science Review 6Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 2Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 3Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 4Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 2Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 4
... Incorporated (Nasdaq: SPEX ), an innovator in ... and regulatory consulting services to food, supplement, biotechnology and ... the 2009 BIO International Conference in Atlanta, Georgia on ... Control Drug" booth will showcase their ongoing global phase ...
... Biomarkers and Non-Invasive Imaging to Demonstrate Mechanism of Action ... May 14 VIA Pharmaceuticals, Inc. (Nasdaq: ... of compounds for the treatment of cardiovascular and metabolic ... a Phase 2 clinical trial of its lead drug, ...
... manufacturing facility opens with substantially increased capacity, ... Biosystems Inc. (TSX:MBX) announced today robust double digit growth ... for the second quarter ended March 31, 2009. , ... of Microbix said "Our 43% growth in the first ...
Cached Biology Technology:Spherix to Exhibit at the BIO 2009 International Convention 2VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 2VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 3VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 4VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 5Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09 2Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09 3Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09 4
(Date:8/25/2015)... and BELLEVUE, Wash. , Aug. ... advanced robotic systems, announced today it will unveil its ... vehicle (UGV), at the National Tactical Officers Association Conference ... The Guardian S is the first-ever commercially available ... years of research and in-field trials and is protected ...
(Date:8/20/2015)... CT ., Aug. 20, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... announces it has joined The Smart Card Alliance and ... Smart Card Alliance and the Smart Card Alliance Latin ... visibility to industry peers and thought leaders promoting adoption ...
(Date:8/12/2015)... , Aug. 12, 2015   MedNet Solutions ... the entire spectrum of clinical research, is proud to ... the company,s comprehensive SaaS-based eClinical technology platform, has led ... the first two quarters of 2015.   Q2 2015 ... largest quarters measured by contract value sold in the ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2
... United States and Great Britain will speak at The ... and his theory of evolution, which continues to excite ... Darwins death. , The free one-day symposium will be ... 5:00 p.m. at The Field Museums James Simpson Theater. ...
... Darwin Foundation (CDF) botanists have published a list of ... Island, the third largest town in Galapagos. 261 species ... Despite 95% of the archipelago falling under the ... areas are having large impacts on the native flora ...
... in an intermittent on/off switch for a gene involved in ... found in a study of human brain tissue. The ... high rates during normal development of the prefrontal cortex, the ... and decision-making but that this normal increase may not ...
Cached Biology News:Darwin Symposium at Field Museum offers broad overview of his science and its impact 2Darwin Symposium at Field Museum offers broad overview of his science and its impact 3How schizophrenia develops: Major clues discovered 2
Mycoplasma Removal Agent (MRA) has been developed for cell culture, to combat the widespread problems caused by contamination of cell cultures with mycoplasma....
Request Info...
albumin from bovine serum (BSA), BODIPY® FL conjugate...
... (6-28) (human, bovine, porcine, rat) ... (VIP) receptor antagonist. This carboxy-terminal ... be twofold more potent than ... antagonists. Storage: ...
Biology Products: